News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Genetic markers being used to target oral hepatitis C drug

Please note embargo:

Pharmac_P540c

Genetic markers being used to target new oral hepatitis C drug

A person’s genetic makeup will be used to target a new funded oral treatment for hepatitis C patients from 1 September.

PHARMAC will begin funding boceprevir (Victrelis) from 1 September 2013 for certain patients with the chronic liver infection. Boceprevir will be funded when used as a triple therapy in combination with pegylated interferon with ribavirin.

PHARMAC Medical Director Dr Peter Moodie says many hepatitis C patients do not respond well to current treatments, but that this could improve with the addition of boceprevir.

“Clinical evidence shows that, given the genetic characteristics of a patient, a simple genetic test can fairly accurately predict how they might respond to treatment,” says Dr Moodie.

“There is a group who we know respond poorly to current treatment. They are the ones we think will benefit most from the addition of this new treatment.”

About 25-35% of patients with certain genes showed a sustained response to the currently available treatment of pegylated interferon and ribavirin. By adding boceprevir to the treatment of these patients, the response rate increases to 70–75%.

As well as adding greater effectiveness to available treatments, Dr Moodie says boceprevir is the first funded oral treatment specifically for hepatitis C.

Patients will be genetically tested to determine whether they qualify for boceprevir (in combination with pegylated interferon and ribavirin) as a first-line treatment.

Boceprevir will also be funded for people who have tried but not responded completely to a course of pegylated interferon and ribavirin.

Dr Moodie says though many people live with hepatitis C without ever knowing it, the infection can cause significant health issues including hepatocellular carcinoma, liver failure, which may require a liver transplant.

Pharmacological treatment aims to reduce the likelihood of these transplants being required. In total, PHARMAC expects around 300 patients to start triple therapy in the next year.

In addition to funding boceprevir, PHARMAC has negotiated a price reduction for the Pegasys brand of pegylated interferon with ribavirin. Together, the funding of these hepatitis C treatments will cost $17.8 million over five years, with some of this cost being refunded through confidential rebates negotiated with both suppliers.

ENDS


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Scoop Review Of Books: Excerpt - Ice Bear: The Cultural History Of An Arctic Icon

“During the last decade the image of the polar bear has moved in the public imagination from being an icon of strength, independence and survival in one of the most climatically extreme of world environments, to that of fragility, vulnerability and more generally of a global environmental crisis.” More>>

NZ Opera: Max Rashbrooke Reviews The Mikado

So concerns about the work of the piece have to be addressed; but they are complex, and probably better handled in another post. So what about this production itself? More>>

Scoop Review Of Books: The Typewriter Factory

I finished reading Don’t Dream It’s Over not long after it came out last August. I even started writing a review, which took something of an ‘I’m sorry people, but it’s already over’ approach. I’ve been pretty negative about journalism as it’s practiced in the mainstream (or MSM, or corporate media or liberal media or whatever terminology you prefer) for quite some time (see for example Stop the Press), and I believe the current capitalist media model is destructive and can’t be reformed. More>>

Sheep Update: Solo World Shearing Record Broken In Southland

Southland shearer Leon Samuels today set a new World solo eight-hours strongwool ewe-shearing after a tally of 605 in a wool shed north of Gore. More>>

ALSO:

Howard Davis Review: Dick Frizzell At The Solander Gallery

One of the most influential and celebrated contemporary Pop artists working in New Zealand, Dick Frizzell is mostly known for his appropriation of kitsch Kiwiana icons, which he often incorporates into cartoon-like paintings and lithographs. Not content with adhering to one particular style, he likes to adopt consciously unfashionable styles of painting, in a manner reminiscent of Roy Lichtenstein. More>>

Old Music: Pop Icon Adam Ant Announces NZ Tour

Following his recent sold out North American and UK tours, Adam Ant is celebrating the 35th anniversary of the release of his landmark KINGS OF THE WILD FRONTIER album with a newly-remastered reissue (Sony Legacy) and Australasian tour. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news